Journal: The Journal of Infectious Diseases

Article Title: FGF8 Protects Against Polymicrobial Sepsis by Enhancing the Host's Anti-infective Immunity

doi: 10.1093/infdis/jiae559

Figure Lengend Snippet: FGFR1 plays a critical role in FGF8-induced protection against experimental sepsis. A , Representative confocal images of the colocalization of FGF8 (Cy3) and FGFR (FITC) in peritoneal macrophages treated with rFGF8 (200 ng/mL). Scale bar = 20 μm. B , Peritoneal macrophages were pretreated with or without rFGF8 (200 ng/mL) followed by incubation with or without heat-inactivated Pseudomonas aeruginosa. Representative fluorescence images of phospho-FGFR1 expression are shown. Scale bar = 25 μm. C , Peritoneal macrophages (n = 4 per group) were pretreated with or without the FGFR1 inhibitor PD173074 (100 nM) for 1 hour followed by incubation with or without rFGF8 (200 ng/mL). In vitro bacterial phagocytosis and killing of P. aeruginosa . D , Mortality after blocking FGFR1 with PD173074 (1 mg/kg) and subsequent treatment with rFGF8 (12.5 μg/kg) or PBS control after CLP (n = 15 per group). Except for survival ( D ), data are presented as means and are representative of 3 independent experiments; ( C ) Kruskal-Wallis test followed by Dunn multiple comparisons posttest; ( D ) Kaplan-Meier analysis followed by log-rank test. * P < .05, *** P < .001, **** P < .0001 compared within 2 groups. Abbreviations: CLP, cecal ligation and puncture; FGFR, FGF receptor; ns, not significant; rFGF, recombinant fibroblast growth factor; FITC, Fluorescein Isothiocyanate; Cy3, Cyanine 3.

Article Snippet: For in vivo blocking of FGFR1 and ERK1/2, PD173074 (1 mg/kg; HY-10321, MedChem Express) and U0126 (10 mg/kg; HY-12031A, MedChem Express) were dissolved in dimethyl sulfoxide (DMSO) solution (10% DMSO + 90% corn oil) and administrated immediately following CLP, respectively.

Techniques: Incubation, Fluorescence, Expressing, In Vitro, Blocking Assay, Control, Ligation, Recombinant

Journal: eLife

Article Title: High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss

doi: 10.7554/elife.52709

Figure Lengend Snippet: Figure 6. Phytate-mediated Ca2+ deficiency promotes vitamin D insufficiency and renal phosphate wasting independent of FGF23 expression. (A–C) Time-course analysis of serum levels of intact PTH (A), 25(OH)D (B), and 1,25(OH)2D (C) in rats fed control, HP-LCa2+, and HP-HCa2+ diets. For the early measurement of 25(OH)D (B) and 1,25(OH)2D, we pooled the sera from 2 to 3 rats. (D–F) Time-course analysis of renal CYP27B1 (D), CYP24A1 (E), and VDR (F) in rats fed control, HP-LCa2+, and HP-HCa2+ diets. (G) Immunoblot analysis of renal aKlotho, NHERF1, NaPi-2a in rats fed control, HP-LCa2+, Figure 6 continued on next page

Article Snippet: Key resources table Reagent type (species) or resource Designation Source or reference Identifiers Additional information Genetic reagent (Rattus norvegicus) Sprague Dawley rat Orient Bio, Seoul, Korea Developed by Sprague Dawley, Inc. Chemical compound, drug AIN-93G Dyets Inc. DYET# 10700 Control diet Chemical compound, drug Phytic acid Sigma-Aldrich Cat. #: P-8810 Phytate diet Chemical compound, drug HNO3 Sigma-Aldrich Cat. #: 438073 Fecal mineral analysis Chemical compound, drug HF Sigma-Aldrich Cat. #: 695068 Fecal mineral analysis Chemical compound, drug HCl Sigma-Aldrich Cat. #: H1758 Fecal mineral analysis Chemical compound, drug EDTA Sigma-Aldrich Cat. #: 93283 Fecal phytate analysis Chemical compound, drug NaOH Sigma-Aldrich Cat. #: 415413 Fecal phytate analysis Chemical compound, drug Calcium Beckman Coulter OSR6113 Serum/urine biochemistry Chemical compound, drug Phosphate Beckman Coulter OSR6122 Serum/urine biochemistry Chemical compound, drug BUN (Urea) Beckman Coulter OSR6134 Serum/urine biochemistry Chemical compound, drug Creatinine Beckman Coulter OSR6178 Serum/urine biochemistry Chemical compound, drug Magnesium Beckman Coulter OSR6189 Serum/urine biochemistry Chemical compound, drug Urine protein Beckman Coulter OSR6170 Urine biochemistry Commercial assay or kit Rat intact PTH Immutopics Cat. #: 60–2500 ELISA kit Commercial assay or kit Human PTH Abcam Cat. #: ab230931 ELISA kit Commercial assay or kit Rat soluble RANKL Immundiagnostik Cat. #: K1019 ELISA kit Commercial assay or kit Rat osteoprotegerin Alpco Immunoassay Cat. #: 30–1020 ELISA kit Commercial assay or kit Rat intact FGF23 Elabscience Cat. #: E-EL-R3031 ELISA kit Commercial assay or kit Rat C-terminal FGF23 Elabscience Cat. #: E-EL-RB0377 ELISA kit Commercial assay or kit Human FGF23 Elabscience Cat. #: E-EL-H1116 ELISA kit Commercial assay or kit 25(OH)-Vitamin D Abbott/USA ARCHITECT 25-OH Vitamin D Chemiluminescence microparticle immunoassay Commercial assay or kit 1,25-(OH)two vitamin D DIAsoure 1,25(OH)2-VIT, D-RIA-CT/Belgium Radioimmunoassay Continued on next page Kim et al. eLife 2020;9:e52709.

Techniques: Expressing, Control, Western Blot

Journal: eLife

Article Title: High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss

doi: 10.7554/elife.52709

Figure Lengend Snippet: Figure 6. Phytate-mediated Ca2+ deficiency promotes vitamin D insufficiency and renal phosphate wasting independent of FGF23 expression. (A–C) Time-course analysis of serum levels of intact PTH (A), 25(OH)D (B), and 1,25(OH)2D (C) in rats fed control, HP-LCa2+, and HP-HCa2+ diets. For the early measurement of 25(OH)D (B) and 1,25(OH)2D, we pooled the sera from 2 to 3 rats. (D–F) Time-course analysis of renal CYP27B1 (D), CYP24A1 (E), and VDR (F) in rats fed control, HP-LCa2+, and HP-HCa2+ diets. (G) Immunoblot analysis of renal aKlotho, NHERF1, NaPi-2a in rats fed control, HP-LCa2+, Figure 6 continued on next page

Article Snippet: Key resources table Reagent type (species) or resource Designation Source or reference Identifiers Additional information Genetic reagent (Rattus norvegicus) Sprague Dawley rat Orient Bio, Seoul, Korea Developed by Sprague Dawley, Inc. Chemical compound, drug AIN-93G Dyets Inc. DYET# 10700 Control diet Chemical compound, drug Phytic acid Sigma-Aldrich Cat. #: P-8810 Phytate diet Chemical compound, drug HNO3 Sigma-Aldrich Cat. #: 438073 Fecal mineral analysis Chemical compound, drug HF Sigma-Aldrich Cat. #: 695068 Fecal mineral analysis Chemical compound, drug HCl Sigma-Aldrich Cat. #: H1758 Fecal mineral analysis Chemical compound, drug EDTA Sigma-Aldrich Cat. #: 93283 Fecal phytate analysis Chemical compound, drug NaOH Sigma-Aldrich Cat. #: 415413 Fecal phytate analysis Chemical compound, drug Calcium Beckman Coulter OSR6113 Serum/urine biochemistry Chemical compound, drug Phosphate Beckman Coulter OSR6122 Serum/urine biochemistry Chemical compound, drug BUN (Urea) Beckman Coulter OSR6134 Serum/urine biochemistry Chemical compound, drug Creatinine Beckman Coulter OSR6178 Serum/urine biochemistry Chemical compound, drug Magnesium Beckman Coulter OSR6189 Serum/urine biochemistry Chemical compound, drug Urine protein Beckman Coulter OSR6170 Urine biochemistry Commercial assay or kit Rat intact PTH Immutopics Cat. #: 60–2500 ELISA kit Commercial assay or kit Human PTH Abcam Cat. #: ab230931 ELISA kit Commercial assay or kit Rat soluble RANKL Immundiagnostik Cat. #: K1019 ELISA kit Commercial assay or kit Rat osteoprotegerin Alpco Immunoassay Cat. #: 30–1020 ELISA kit Commercial assay or kit Rat intact FGF23 Elabscience Cat. #: E-EL-R3031 ELISA kit Commercial assay or kit Rat C-terminal FGF23 Elabscience Cat. #: E-EL-RB0377 ELISA kit Commercial assay or kit Human FGF23 Elabscience Cat. #: E-EL-H1116 ELISA kit Commercial assay or kit 25(OH)-Vitamin D Abbott/USA ARCHITECT 25-OH Vitamin D Chemiluminescence microparticle immunoassay Commercial assay or kit 1,25-(OH)two vitamin D DIAsoure 1,25(OH)2-VIT, D-RIA-CT/Belgium Radioimmunoassay Continued on next page Kim et al. eLife 2020;9:e52709.

Techniques: Expressing, Control, Western Blot

Journal: Pharmacognosy Magazine

Article Title: Fucoidan Attenuated Kidney and Bone Damage Caused by CKD-MBD in Mice by Upregulating Klotho

doi: 10.1177/09731296231172549

Figure Lengend Snippet: Figure 1. Fucoidan Treatment Reversed the Changes of Serum Biochemical Indexes Caused by the Modeling. A–D, the Levels of BUN, Creatinine, ALP, and Pi in the Serum of Mice in the Five Groups were Detected by an Automatic Biochemical Analyzer. E–G, the Levels of iPTH, FGF23, and 1,25 (OH)2D3 in the Serum of Mice in the Five Groups Were Determined by ELISA. H, the Relative BMD of Mice in the Five Groups Was Measured by X-Ray Densitometers.

Article Snippet: Enzyme-linked Immunosorbent Assay (ELISA) The contents of intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF23), and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, DHVD3) in the serum were measured by the Mouse iPTH ELISA Kit (E-EL-M0709, Elabscience, China), Mouse FGF23 ELISA Kit (E-EL-M2415C, Elabscience, China), and Mouse DHVD3 ELISA Kit (E-EL-0016C, Elabscience, China), respectively.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Molecular medicine reports

Article Title: Reparative effects of chronic intermittent hypobaric hypoxia pre‑treatment on intervertebral disc degeneration in rats.

doi: 10.3892/mmr.2022.12689

Figure Lengend Snippet: Figure 7. Effect of CIHH on the expression of bFGF protein in degeneration disc tissue. (A) Western blotting of bFGF protein at 1, 2, 4 and 8 weeks. (B) Western blotting data distribution of bFGF proteins at 1, 2, 4, and 8 weeks. (C) bFGF protein expression levels at 1, 2, 4, and 8 weeks in three groups. (D) Expression trend of bFGF protein. n=16 for each group; n=4 for each time point. *P<0.05 vs. CON group; #P<0.05 vs. IDD group. bFGF, basic fibroblast growth factor; CIHH, chronic intermittent hypobaric hypoxia; IDD, intervertebral disc degeneration disease group; CON, control.

Article Snippet: The Haematoxylin‐eosin/He Staining kit, Modified Safranine O‐Fast Green FCF Cartilage Stain kit, and Masson's Trichrome Stain kit were purchased from Beijing Solarbio Science & Technology Co., Ltd. Rat bFGF ELISA kit (cat. no. E‐EL‐R0091c), Rat HIF‐1α eliSa kit (E‐EL‐R0513c) and TGF‐β1 ELISA kit (E‐EL‐0162c) were purchased from Elabscience Biotechnology, Inc. For the western blotting experiments, collagen I(WL0088), collagen II(WL03082) and TGF‐β1 (Wl02193) antibodies were purchased from Wanleibio co., ltd., and the bFGF (E‐AB‐15525) antibody was purchased from Elabscience Biotechnology, Inc.

Techniques: Expressing, Western Blot, Control

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: Pyruvate upregulated FGF21 expression and secretion in HepG2 cells. ( A ): pyruvate dose-dependently stimulated FGF21 gene expression after 12 h treatment in HepG2 cells (** p < 0.01 vs. control, n = 3). ( B ): FGF21 protein levels in cell medium significantly increased after pyruvate treatment (** p < 0.01 vs. control, n = 10). ( C ): The cell viability was not influenced by pyruvate treatment, as shown by MTT assay ( n = 10). ( D ): D-LDH levels in cell medium were not changed by pyruvate treatment ( n = 10).

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing, Gene Expression, Control, MTT Assay

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: cAMP reduction caused pyruvate-stimulated FGF21 expression in HepG2 cells. ( A ): The activation of PPAR-α and AMPK was not involved in pyruvate-stimulated FGF21 expression (** p < 0.01 vs. control, n = 3). ( B ): AC activator forskolin, PDE inhibitor IBMX and 8-Bromo-cAMP administration significantly inhibited FGF21 expression and suppressed pyruvate-stimulated FGF21 expression (* p < 0.05 vs. control, # p < 0.05 vs. pyruvate group, n = 3). ( C ): Forskolin, IBMX and 8-Bromo-cAMP inhibited pyruvate-stimulated increase in FGF21 protein levels in cell medium (* p < 0.05 vs. control, # p < 0.05 vs. pyruvate group, n = 10). ( D ): Pyruvate decreased intracellular cAMP levels in HepG2 cells (** p < 0.01 vs. control, n = 12).

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing, Activation Assay, Control

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: Epac and CREB were involved in pyruvate-stimulated FGF21 expression in HepG2 cells. ( A ): Epac inhibitor ESI-09 but not PKA inhibitor H89 upregulated FGF21 expression and eliminated the stimulatory effect of pyruvate on FGF21 expression (** p < 0.01 vs. control, n = 3) ( B ): CREB inhibitor 666-15 upregulated FGF21 expression and eliminated the stimulatory effect of pyruvate on FGF21 expression (** p < 0.01 vs. control, n = 3). ( C , D ): Pyruvate reduced CREB phosphorylation without influencing the total CREB protein levels (** p < 0.01 vs. control, n = 3).

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing, Control, Phospho-proteomics

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: Pyruvate upregulated FGF21 expression and secretion in mouse hepatic AML-12 cells. ( A , B ): Pyruvate stimulated FGF21 expression and secretion in AML-12 cells (* p < 0.05 and ** p < 0.01 vs. control, n = 6). ( C ): Pyruvate decreased intracellular cAMP levels in AML12 cells (* p < 0.05, n = 5). ( D ): Pyruvate increased PDE activities in AML-12 cells (* p < 0.05, n = 5).

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing, Control

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: Pyruvate upregulated FGF21 expression in mice in vivo. ( A ): Intraperitoneal injection of pyruvate significantly increased serum pyruvate levels in C57BL/6J mice compared with the control (** p < 0.01, n = 10). ( B ): The pyruvate-treated mice had significantly higher FGF21 gene expression in liver than the control (** p < 0.01, n = 10). ( C ): Serum FGF21 levels were not changed by pyruvate treatment in mice compared with the control ( n = 10). ( D ): cAMP levels in mouse liver were significantly decreased by pyruvate treatment in mice (* p < 0.05, n = 10). ( E ): PDE activity in mouse liver was significantly activated by pyruvate injection in mice (* p < 0.05, n = 10). ( F ): CREB phosphorylation was inhibited in liver after pyruvate injection compared with the control. ( G , H ): ALT and AST activities in mouse serum were not significantly different between pyruvate-treated group and the control group. ( I ): H&E staining showed that the liver tissues had normal morphology in mice of pyruvate-treated group without obvious difference to the control (bar is 20 μm).

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing, In Vivo, Injection, Control, Gene Expression, Activity Assay, Phospho-proteomics, Staining

Journal: International Journal of Molecular Sciences

Article Title: Pyruvate Upregulates Hepatic FGF21 Expression by Activating PDE and Inhibiting cAMP–Epac–CREB Signaling Pathway

doi: 10.3390/ijms23105490

Figure Lengend Snippet: The diagram of pyruvate-stimulated FGF21 expression in hepatocytes. cAMP–Epac–CREB signaling inhibits FGF21 expression in human and mouse hepatocytes. Pyruvate activates PDEs to reduce cAMP levels and then inhibits cAMP–Epac–CREB signaling to upregulate FGF21 expression in hepatocytes.

Article Snippet: Human and mouse FGF21 ELISA kits, cAMP assay kits, the ALT activity assay kit, the AST activity assay kit and the LDH assay kit were obtained from Elabscience (Wuhan, China).

Techniques: Expressing